bioRxivMicrobiology
A traditional medicine, Respiratory Detox Shot (RDS), inhibits the infection of SARS-CoV, SARS-CoV-2, and the Influenza A virus in vitro
B. Hetrick, D. Yu, A. Olanrewaju, L. Chilin, S. He, D. Debbagh, Y.-C. Ma, L. Hofmann, R. Hakami, Y. Wu
Abstract
The ongoing global pandemic of coronavirus disease 2019 (COVID-19) has resulted in the infection of over 60 million people and has caused over 1.4 million deaths as of December 2020 in more than 220 countries and territories. Currently, there is no effective treatment for COVID-19 to reduce mortality. We investigated the potential anti-coronavirus activities from an oral liquid of traditional medicine, Respiratory Detox Shot (RDS), which contains mostly herbal ingredients traditionally used to manage lung diseases. Here we report that RDS inhibited the infection of target cells by SARS-CoV and SARS-CoV-2 pseudoviruses, and by infectious wild-type SARS-CoV-2. We further demonstrated that RDS inhibits viral early infection steps. In addition, we found that RDS can also block the infection of target cells by Influenza A virus. These results suggest that RDS may broadly inhibit the infection of respiratory viruses.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.
A. J. Pruijssers, A. S. George, … T. P. Sheahan·bioRxiv·Apr 27, 2020
- A novel fermented Yi traditional medicine efficiently suppresses the replication of SARS-CoV-2 in vitro
- Virucidal activity of a proprietary blend of plant-based oils (Viruxal) against SARS-CoV-2 and influenza viruses - an in vitro study
J. M. Kristjansson, O. Rolfsson·bioRxiv·May 31, 2021
- Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models
- Discovery of rhodomyrtone as a broad-spectrum antiviral inhibitor with anti-SARS-CoV-2 activity
- Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo
S. Weston, C. M. Coleman, … M. Frieman·bioRxiv·Mar 25, 2020